Callitas Health (Callitas Health) FCF Margin % : -246.15% (As of Sep. 2020)

View and export this data going back to 2008. Start your Free Trial

What is Callitas Health FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Callitas Health's Free Cash Flow for the three months ended in Sep. 2020 was $-0.10 Mil. Callitas Health's Revenue for the three months ended in Sep. 2020 was $0.04 Mil. Therefore, Callitas Health's FCF Margin % for the quarter that ended in Sep. 2020 was -246.15%.

As of today, Callitas Health's current FCF Yield % is 0.00%.

The historical rank and industry rank for Callitas Health's FCF Margin % or its related term are showing as below:

MPHMF' s FCF Margin % Range Over the Past 10 Years
Min: -34.64 Med: 0 Max: 0
Current: -34.64

MPHMF's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -147.18 vs MPHMF: -34.64

Callitas Health FCF Margin % Historical Data

The historical data trend for Callitas Health's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Callitas Health FCF Margin % Chart

Callitas Health Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

FCF Margin %

Get a 7-Day Free Trial

-480.95

24.55

-162.83

Callitas Health Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
FCF Margin %	Get a 7-Day Free Trial															-1,500.00	-43.48	-20.83	66.30	-246.15

Competitive Comparison of Callitas Health's FCF Margin %

For the Biotechnology subindustry, Callitas Health's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Callitas Health's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Callitas Health's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Callitas Health's FCF Margin % falls into.

Callitas Health FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Callitas Health's FCF Margin for the fiscal year that ended in Dec. 2019 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2019 )	/	Revenue (A: Dec. 2019 )
	=	-0.876	/	0.538
	=	-162.83 %

Callitas Health's FCF Margin for the quarter that ended in Sep. 2020 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2020 )	/	Revenue (Q: Sep. 2020 )
	=	-0.096	/	0.039
	=	-246.15 %

Callitas Health FCF Margin % Related Terms

Thank you for viewing the detailed overview of Callitas Health's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Callitas Health (Callitas Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Callitas Health Inc (OTCPK:MPHMF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

734 - 1055 Dunsmuir Street, Vancouver, BC, CAN, V7X 1B1

Website

http://www.callitas.com

Callitas Health Inc is a clinical-stage company. It is engaged in developing technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The company's products offering includes ToConceive, C-103 Reformulated Orlistat, and Extrinsa. ToConceive is a fertility enhancing moisturizer. It is clinically proven to increase a woman's own natural conception lubrication, called transudate, to aid in conception. Orlistat is FDA-approved for weight management and sold by Roche as Xenical (prescription) and by GlaxoSmithKline as alli. Extrinsa focuses on women with orgasm and arousal difficulties. The topical, local, and the non-systemic product is also non-hormonal and does not affect the central nervous system.